Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research ...

Topics: Corporate, Sanofi, Evotec, infectious diseases Read More

Evotec achieves second milestone in diabetes alliance with Sanofi

Companies are at the forefront of beta cell replacement therapeutic research for diabetes Evotec receives € 3 Million payment from Sanofi Milestone further demonstrates advancement of EVT Innovate initiative “TARGETBCD”

Topics: Corporate, Sanofi, Evotec, beta cell replacement, TARGETBCD, diabetes Read More

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a ...

Topics: Corporate, Sanofi, Evotec, infectious diseases Read More

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center

Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ ...

Topics: Corporate, Evotec, Arix Bioscience, Fred Hutchinson Cancer Research Center Read More

Evotec and Celgene expand IPSC collaboration to include additional cell lines

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More